December 18, 2014 10:34 PM ET

Biotechnology

Company Overview of Autifony Therapeutics Limited

Company Overview

Autifony Therapeutics Limited, a biotechnology company, develops medicines to treat hearing disorders such as hearing loss and tinnitus. The company was incorporated in 2011 and is based in London, United Kingdom.

90 High Holborn

Holborn

London,  WC1V 6XX

United Kingdom

Founded in 2011

Key Executives for Autifony Therapeutics Limited

Co-Founder and Chief Scientific Officer
Co-Founder and Head of Preclinical Drug Discovery
Compensation as of Fiscal Year 2014.

Autifony Therapeutics Limited Key Developments

Autifony Therapeutics Announces Initiation of Phase IIa Study for First-In-Class Drug to Treat Tinnitus

Autifony Therapeutics Limited has initiated a Phase IIa study in tinnitus subjects with its lead compound AUT00063. This proof of concept study (called the QUIET-1 study, QUest In Eliminating Tinnitus) will explore the potential of AUT00063, Autifony’s first-in-class Kv3 potassium channel modulator, to reduce the symptoms of tinnitus, which is an area of significant unmet medical need. In the earlier Phase I study, AUT00063 showed a good safety and tolerability profile, and pharmacokinetics compatible with once daily oral dosing. The Phase IIa study will focus in particular on tinnitus associated with hearing loss following noise exposure or ageing. Subjects will undergo four weeks of once daily dosing. In the earlier Phase I study, AUT00063 showed a good safety and tolerability profile, and pharmacokinetics compatible with once daily oral dosing. The Phase IIa study will focus in particular on tinnitus associated with hearing loss following noise exposure or ageing. Subjects will undergo four weeks of once daily dosing. AUT00063 is also in development for the treatment of age-related hearing loss and a Phase IIa clinical trial in this indication is expected to start soon in the US.

Autifony Therapeutics Collaborates with University of Manchester and Newcastle University to Develop First-in-Class Treatment for Schizophrenia

Imperial Innovations Group plc announced that its portfolio company, Autifony Therapeutics is collaborating with research groups at the University of Manchester and Newcastle University to develop a first-in-class treatment for schizophrenia. The £2.75 million research collaboration is part-funded by the Biomedical Catalyst which awarded a £1.9 million grant to Autifony and the two Universities. The funding will enable selection and progression of a compound from a group of potential candidates through to application to conduct clinical trials. Schizophrenia is a serious psychiatric illness that has a high unmet need and imposes a huge social and economic burden. Research into schizophrenia has seen diminishing investment in recent years, with existing schizophrenia treatments demonstrating poor efficacy and considerable side effects for many patients. Autifony recently initiated a Phase I clinical study, expected to complete in the first quarter of 2014, as part of its lead programme to develop first-in-class drugs for hearing loss and tinnitus.

Autifony Therapeutics Initiates Phase I Trial for Treatment of Hearing Loss and Tinnitus

Imperial Innovations Group plc announced that its portfolio company, Autifony Therapeutics has initiated a Phase I clinical study of AUT00063, its lead product for the treatment of  hearing disorders. The study, being conducted in the UK, will investigate the safety and optimal dosing regimens of AUT00063 in around 60 young and elderly volunteers, and is expected to complete in first quarter of 2014. Autifony has recently received £5 million in investment funding from Pfizer Venture Investments, the venture capital arm of Pfizer Inc.  The International Biotechnology Trust PLC (IBT) has also invested, bringing the total funds raised in this recent funding round to £15.75 million. Existing investors include SV Life Sciences, UCL Business plc (UCLB) and Imperial Innovations, which has invested a total of £5 million in Autifony. Despite the fact that 50% of those aged over 60 suffer from age-related hearing loss and 10% of the population suffer from some form of tinnitus, there is currently no effective treatment for either condition. AUT00063 is a novel pharmaceutical treatment that targets auditory processing in the brain. Deficits in these central mechanisms are believed to contribute to hearing difficulties in the elderly as well as the emergence of tinnitus.

Similar Private Companies By Industry

Company Name Region
Anglo Biotrans Plc Europe
Celgene Limited (Ireland) Europe
Celsis International Ltd. Europe
GE Healthcare Bio-Sciences UK Ltd. Europe
Wildlife DNA Services Ltd. Europe

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Autifony Therapeutics Limited, please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.